Corton Capital’s Viridian Therapeutics VRDN Stock Holding History

Corton Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$213K	Sell	9,864 -7,903	-44%	-$143K	0.52%	95
2025 Q2	$248K	Buy	+17,767	New	+$241K	0.29%	132
2025 Q1	–	Sell	-12,702	Closed	-$243K	–	423
2024 Q4	$243K	Sell	12,702 -3,103	-20%	-$67.5K	0.14%	189
2024 Q3	$360K	Sell	15,805 -15,927	-50%	-$260K	0.17%	133
2024 Q2	$413K	Buy	31,732 +12,662	+66%	+$175K	0.22%	92
2024 Q1	$334K	Buy	19,070 +561	+3%	+$10.9K	0.12%	239
2023 Q4	$403K	Buy	+18,509	New	+$292K	0.13%	222

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Corton Capital's VRDN Position: Q3 2025 in Review

Corton Capital reduced its Viridian Therapeutics (VRDN) stake by 44% in Q3 2025, selling an estimated $143K and leaving 9,864 shares worth $213K. The position accounts for 0.52% of the portfolio, ranked #95.

Corton Capital first reported a position in VRDN in Q4 2023 and has held it in 7 quarters since. The position peaked at $413K in Q2 2024. 169 funds tracked by Wall St. Rank hold VRDN as of Q3 2025.

Corton Capital held 9,864 shares of Viridian Therapeutics worth $213K as of Q3 2025.
Corton Capital sold 7,903 Viridian Therapeutics shares in Q3 2025, an estimated $143K.
Viridian Therapeutics made up 0.52% of Corton Capital's portfolio in Q3 2025, its #95 holding.
Corton Capital first reported a position in Viridian Therapeutics in Q4 2023 and has held it in 7 quarters since.
Corton Capital's Viridian Therapeutics position peaked at $413K in Q2 2024.
169 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.